Journal News

Targeting toxins to treat whooping cough

Isabel Casas Emily Ulrich
May 1, 2025

Whooping cough is an infectious respiratory disease caused by the bacteria Bordetella pertussis. According to the U.S. Centers for Disease Control and Prevention, whooping cough cases are rising. While early antibiotic treatment can be effective, most diagnoses do not occur until after this therapeutic window has passed.

Whooping cough bacteria
Whooping cough bacteria

In a recent Journal of Biological Chemistry article , Stefanie Lietz from Ulm University, Germany, and an international team explored the human peptidome — the complete collection of peptides in the human body — for pertussis toxin, or PT, inhibitors using peptide libraries, fractionation and mass spectrometry. They identified the liver protein α1-antitrypsin, or α1AT, as a potent PT inhibitor. Additional cell culture and molecular modeling experiments indicated that α1AT likely binds to PT in solution and thus blocks the toxin from making contact with its known host glycoprotein cell surface interaction partner for endocytosis.

Patients with genetic α1AT deficiency receive synthetic α1AT in the clinic. Therefore, α1AT may be able to be repurposed to treat PT-mediated pertussis pathogenesis. Future studies will fill in details about α1AT’s mechanism of action against PT, such as verifying the α1AT residues involved in binding PT.

Enjoy reading ASBMB Today?

Become a member to receive the print edition four times a year and the digital edition monthly.

Learn more
Isabel Casas

Isabel Casas is the ASBMB’s publications director.

Emily Ulrich

Emily Ulrich is the ASBMB’s science editor.

Get the latest from ASBMB Today

Enter your email address, and we’ll send you a weekly email with recent articles, interviews and more.

Latest in Science

Science highlights or most popular articles

Defeating deletions and duplications
News

Defeating deletions and duplications

July 11, 2025

Promising therapeutics for chromosome 15 rare neurodevelopmental disorders, including Angelman syndrome, Dup15q syndrome and Prader–Willi syndrome.

Using 'nature’s mistakes' as a window into Lafora disease
Feature

Using 'nature’s mistakes' as a window into Lafora disease

July 10, 2025

After years of heartbreak, Lafora disease families are fueling glycogen storage research breakthroughs, helping develop therapies that may treat not only Lafora but other related neurological disorders.

Cracking cancer’s code through functional connections
News

Cracking cancer’s code through functional connections

July 2, 2025

A machine learning–derived protein cofunction network is transforming how scientists understand and uncover relationships between proteins in cancer.

Gaze into the proteomics crystal ball
In-person Conference

Gaze into the proteomics crystal ball

July 1, 2025

The 15th International Symposium on Proteomics in the Life Sciences symposium will be held August 17–21 in Cambridge, Massachusetts.

Bacterial enzyme catalyzes body odor compound formation
Journal News

Bacterial enzyme catalyzes body odor compound formation

June 27, 2025

Researchers identify a skin-resident Staphylococcus hominis dipeptidase involved in creating sulfur-containing secretions. Read more about this recent Journal of Biological Chemistry paper.

Neurobiology of stress and substance use
Profile

Neurobiology of stress and substance use

June 19, 2025

MOSAIC scholar and proud Latino, Bryan Cruz of Scripps Research Institute studies the neurochemical origins of PTSD-related alcohol use using a multidisciplinary approach.